BACKGROUND:Aflatoxin serves as a distinct risk factor for hepatic carcinoma, making the investigation into its association with hepatic carcinoma is essential for unraveling the molecular underpinnings of oncogenesis and devising therapeutic strategies for tumors. However, the mechanism by which aflatoxin causes liver cancer is not yet clear. This article aims to analyze the latest research progress and cutting-edge exploration directions for aflatoxin-induced liver cancer. METHOD:This research relies on the Web of Science core collection for information retrieval, leveraging the broad scope of the SCI-EXPANDED index to guarantee comprehensiveness and high precision of the gathered data. From April 30, 2014 to April 30, 2024, relevant original research literature and reviews on aflatoxin and liver cancer were retrieved. Subsequently, VOSviewer, CiteSpace, and R software were used to visualize and analyze the articles. RESULTS:A total of 597 relevant studies were obtained, with 3228 authors from 1116 organizations in 94 countries. America and China are major contributors to international publications. Groopman, John D has the most publications, and Jessica Zucman-Rossi has the highest number of citations. Guangxi Medical University, China Agricultural University, Johns Hopkins University, etc were the main research institutions. Toxins, Food and Chemical Toxicology are popular journals in this field, and the most cited journal is Nature Reviews Gastroenterology & Hepatology. Research primarily focuses on 4 areas: the correlation between aflatoxin contamination, exposure levels, and the progression of hepatic carcinoma; the underlying processes by which aflatoxin inflicts liver injury that may result in hepatic carcinoma; the combined impact of aflatoxin B1 and the hepatitis B virus (HBV) on the onset of hepatic carcinoma; and strategies for the prevention and management of aflatoxin-induced hepatic malignancies. Specifically, aflatoxins can induce hepatotoxicity, immunotoxicity, alter expression of coding genes and noncoding RNAs, and synergize with hepatitis B virus to promote hepatocarcinogenesis. Physical, chemical, and biological methods have been widely employed to degrade aflatoxins for liver cancer prevention and control, among which biological control have garnered significant attention from researchers. CONCLUSION:Research on the aflatoxin-hepatic carcinoma link is rapidly advancing. Furthermore, it confirms aflatoxin's pivotal role in the pathogenesis of liver cancer.

Background:Traditional Chinese medicine (TCM) demonstrates growing potential in liver cancer management, yet a comprehensive overview mapping the intellectual landscape and evolving trends of this field is lacking. This study aims to fill this gap by conducting a systematic bibliometric analysis of TCM for liver cancer research over the past decade. Methods:We performed a bibliometric analysis of publications related to TCM and liver cancer retrieved from major databases including China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and Web of Science. The search timeframe spanned from February 14, 2015, to the search date (February 14, 2025). The literature was analyzed using scientific mapping tools, such as CiteSpace, Origin 2024, R, and VOSviewer, to identify publication trends, collaborative networks, research hotspots, and frontier topics. Results:The analysis reveals a steadily growing and globally engaged field, with China being the dominant contributor. While core research teams are emerging, international and cross-regional collaborations remain limited. A clear thematic divergence exists: international literature primarily focuses on exploring the pharmacological mechanisms of TCM compounds, whereas Chinese-language studies place greater emphasis on clinical applications, medication rules, data mining, and TCM syndrome differentiation. Key emerging research frontiers include mechanisms of action, omics technologies, bioinformatics technology, network pharmacology and molecular docking, TCM syndrome research, TCM theory innovation and exploration, TCM nanodelivery, data mining, and deep learning. Conclusion:This bibliometric review provides a comprehensive landscape of TCM research for liver cancer, highlighting its dynamic growth and the complementary nature of mechanistic and clinical research streams. The findings underscore the necessity for enhanced international collaboration to bridge existing gaps and foster integrated, innovative approaches for advancing TCM in oncology.

We present a case of rosacea recurrence in a 37-year-old woman associated with the intake of compound vitamin tablets during the preconception period, with a Naranjo score of 7. These tablets, commonly used for nutritional supplementation to prevent anemia, contain a variety of vitamins, minerals, and trace elements. Despite their widespread use, reports of such supplements causing rosacea recurrence are rare. In this case, the patient experienced a recurrence of facial redness, stinging, and burning after taking the tablets on two separate occasions. Skin dermatoscopy, VISIA imaging, Clinician's Erythema Assessment (CEA), Investigator's Global Assessment (IGA), and Visual Analogue Scale (VAS) all confirmed the recurrence of rosacea. Given her intention to conceive, symptomatic treatment with emollient and reparative dressings was administered. The patient's symptoms gradually resolved after discontinuing the medication, with no recurrence observed during follow-up visits. Women with a history of rosacea should avoid these tablets during preconception, pregnancy, and lactation to prevent recurrence and should choose supplements carefully to minimize the risk of rosacea flare-ups.

Introduction:Non-small cell lung cancer (NSCLC) stands as one of the most prevalent malignancies, and chemotherapy remains the primary treatment for advanced stages. However, the high expression of ABC binding cassette transporters, including MRP, P-gp, and LRP, along with multidrug resistance proteins, has been identified as a significant factor contributing to decreased chemotherapy drug sensitivity. This study aims to explore the impact and underlying mechanisms of Curculiginis Rhizoma [Hypoxidaceae; Curculigo orchioides Gaertn.] (CR) in combination with cisplatin on improving chemoresistance mediated by ABC binding cassette transporters and multidrug resistance proteins in NSCLC.Methods and Results:To unravel the relationship between JNK, MRP, P-gp, and LRP in NSCLC and gain insights into the regulatory mechanism of CR, this study employs an integrated approach encompassing bioinformatics, molecular docking, molecular dynamics, animal and cellular experiments. Bioinformatics analysis revealed a significant increase in the expression levels of JNK, MRP, P-gp, and LRP subtypes in multidrug-resistant non-small cell lung cancer. Subsequent animal experiments have shown that the combination of CR with cisplatin can improve the survival rate of lung cancer mice. Molecular docking and molecular dynamics analyses demonstrated favorable binding interactions between curculigoside and the aforementioned subtypes of JNK, MRP, P-gp, and LRP. In cellular experiments, the combination of cisplatin with both curculigoside and CR extract resulted in a notable decrease in cell viability and downregulation of the expression of JNK1, JNK2, MRP1, MRP2, MRP4, P-gp, and LRP1 in A549/cis cells.Conclusion:Remarkably, curculigoside exerted a significant downregulation effect on the expression levels of JNK1, MRP1, MRP2, MRP4, and LRP1. CR, particularly its main effective metabolite, curculigoside, has the potential to enhance the sensitivity of non-small cell lung cancer to cisplatin by regulating levels of JNK/MRP/LRP/P-gp and mitigating multidrug resistance.

目的:观察川芎嗪(四甲基吡嗪)对耐药相关ATP结合盒转运体B1(ABCB1)、C1(ABCC1)和G2(ABCG2)表达水平的影响,揭示其逆转人非小细胞肺癌顺铂耐药细胞株A549/DDP耐药的机制.方法:采用细胞增殖(CCK8)实验,分析人肺腺癌细胞株A549 及顺铂耐药株A549/DDP对顺铂的耐受性,计算耐药指数.分析A549/DDP对川芎嗪的耐受性,遴选逆转耐药所需的工作浓度并检测逆转效果.设置空白组接种A549 细胞,模型组、实验组和阳性对照组均接种A549/DDP细胞;空白组和模型组均用 1640 完全培养基孵育,实验组用含工作浓度川芎嗪的 1640 完全培养基孵育,阳性对照组用含Tariquidar的 1640 完全培养基孵育.提取各组全部蛋白及mRNA,用免疫印迹法(Western Blot)和逆转录-聚合酶链反应(RT-PCR)分析川芎嗪对ABCB1、ABCC1 和ABCG2 及其mRNA表达水平的影响.结果:A549 细胞对顺铂的半数抑制浓度(IC50)为(28.33±3.19)μM,A549/DDP对顺铂的IC50 为(983.43±101.67)μM,A549/DDP的耐药指数为 34.71.当川芎嗪浓度不高于 150 μM时,A549/DDP细胞活性无影响,遴选 100 μM为川芎嗪逆转耐药的工作浓度,1 μM作为阳性对照药Tariquidar的工作浓度.川芎嗪逆转耐药指数为 7.68,Tariquidar为 5.74.Western Blot实验发现,模型组ABCB1、ABCC1 和ABCG2 的表达水平均高于空白组,在实验组和阳性对照组中均不同程度下调,差异有统计学意义(P＜0.05).RT-PCT实验显示,实验组和阳性对照组ABCB1 和ABCC1 mRNA的表达水平与模型组比较均有不同程度的下调(P＜0.05),但ABCG2 mRNA的表达水未见明显变化(P＞0.05).结论:川芎嗪可下调ABCB1、ABCC1 和ABCG2 的表达水平,此可能为逆转A549/DDP细胞对顺铂耐受性的机制之一.

At present,there are problems in the construction of guidelines of clinical application of Chinese patent medicines:little high-quality clinical evidence,generally not high recommendation strength,missing or inconsistent evidence classification and recommendation standards,insufficient building of relevant guidelines for Western physicians,not timely revision of some guidelines,insufficient building of relevant guidelines of some dominant diseases treated with TCM,and insufficient extensiveness and representativeness of some guideline makers.In the future,it is necessary to strengthen the research level of clinical trials of Chinese patent medicines to improve the quality of clinical evidence;appropriately expand the sources of clinical evidence;try to establish evidence classification and recommendation standards that meet the characteristics of TCM;strengthen the guideline description in modern medical language;further standardize and improve the instructions of Chinese patent medicines;revise relevant guidelines in time based on the latest clinical evidence;further strengthen the building of relevant guidelines for the treatment of serious and chronic diseases;standardize,formulate and publish guidelines at the national level;actively refer to the published guidelines.

目的:了解培美曲塞致假性蜂窝织炎的临床特点.方法:检索国内外数据库,收集培美曲塞致假性蜂窝织炎的病例报告类文献,提取患者相关信息(性别、年龄、原发疾病、联合用药、发生时间、不良反应发生情况、检验检查指标、主要干预措施及转归、是否再次使用等)进行描述性统计分析.结果:共收集到 17 例培美曲塞致假性蜂窝织炎病例,其中男性患者 10 例,女性患者7 例;年龄为 36～79 岁,中位年龄为 66 岁.假性蜂窝织炎的发生时间为使用培美曲塞的第 1 周期至第 21 周期,中位发生时间为第4 周期.临床表现主要为双下肢的肿胀(13 例,占76.47%)、皮疹(13 例,占76.47%)、疼痛(10 例,占58.82%)和硬化(6 例,占35.29%)等.7 例患者初始抗菌药物治疗无效;4 例患者抗菌药物治疗无效后换用外用皮质激素类药物治疗,皮疹缓解.4 例患者初始口服或外用糖皮质激素治疗后,症状均得以缓解.多数患者治疗后好转,1 例患者由于原患疾病加重而死亡,2 例患者皮疹部位持续硬化.结论:培美曲塞所致假性蜂窝织炎的临床表现多为双下肢的肿胀、皮疹、疼痛和硬化等,多数患者治疗后好转,少数可出现皮疹部位持续硬化.使用培美曲塞后,若出现类似蜂窝织炎症状,应及时与感染性疾病蜂窝织炎进行鉴别诊断,给予口服或外用皮质激素类药物治疗,保障患者用药安全.

目的 了解蒲地蓝消炎口服液在儿童中的应用情况,评价其在真实世界中用法用量及安全性,为临床儿童合理用药提供数据支持.方法 收集2017年1月至2021年12月8家三甲中医院含蒲地蓝消炎口服液的儿童处方25964张.从患儿年龄、性别、给药频次、日剂量、临床诊断等方面,对蒲地蓝消炎口服液儿童临床应用情况进行统计分析.结果 3～6岁患儿占比最多(10430张,占40.17％);男性患儿14378张,约为女性患儿(11586张)的1.24倍;占比最大的单次剂量、给药频次和日剂量分别为10 ml(20721张,占79.81％)、3次/d(22559张,占86.89％)、30 ml/d(18114张,占69.77％);临床诊断以上呼吸道感染为主(18586张,占71.58％).结论 蒲地蓝消炎口服液多用于3～6岁男性患儿,存在给药剂量、频次超专家共识推荐,临床诊断超说明书适应证等情况.

Rationale:Gefitinib is a potent and selective orally active growth factor receptor (EGFR)-tyrosine kinase inhibitor that is commonly used to treat advanced non-small cell lung cancer patients with activating EGFR mutations. Hearing impairment with gefitinib was sparsely reported. In this report, we describe a case of sensorineural deafness associated with the administration of gefitinib, with a Naranjo score of 7.Patient concerns:An 81-year-old female was diagnosed with lung adenocarcinoma with bone metastasis and an EGFR-activating mutation. The patient was prescribed gefitinib tablets at a daily dose of 250 mg for lung adenocarcinoma treatment. However, the patient experienced moderate to severe bilateral sensorineural deafness, primarily in her right ear, after taking gefitinib. Following the cessation of gefitinib administration, the patient exhibited partial restoration of auditory function. Upon resuming the medication, she experienced a worsening of deafness.Diagnoses:The otoscopic audiogram and hearing test indicated moderate to severe bilateral sensorineural deafness.Interventions:The otolaryngologist recommended bilateral hearing aids to enhance hearing function.Outcomes:Throughout our follow-up period, the patient did not receive a hearing aid implant.Lessons:This article first reported the ototoxicity caused by gefitinib. While rare, our report highlights that gefitinib-induced sensorineural deafness is possible and its mechanisms are still unclear. This adverse reaction should be monitored closely during clinical application of gefitinib to improve patient outcomes.

目的 分析矿物药治疗抑郁症的用药规律,为临床治疗抑郁症提供参考.方法 收集首都医科大学附属北京安定医院门诊2020 年 1 月至 2022 年 12 月治疗抑郁症的中药饮片处方,归纳处方所用矿物药的名称、功效、性味、归经及其相应使用频次及频率分布情况.结果 共纳入中药饮片处方 634 首,涉及中药 211 味,其中矿物药 14 味.所用矿物药以平肝熄风药(647 次、54.14%)、清热药(263 次、22.01%)、安神药(207 次、17.32%)为主,具体功效以平肝潜阳(667 次、55.82%),重镇安神(610 次、51.05%),定惊清肝明目(457 次、38.24%)较多.使用频次排名前 4 的为珍珠母(433 次、36.23%),生石膏(263 次、22.01%),生牡蛎(171 次、14.31%)和生龙骨(148 次、12.38%).药性以寒性居多(包括大寒、寒、微寒,977 次、81.76%);药味以咸味居多(716 次、43.77%),归经以肝经(928 次、33.15%)、心经(653 次、23.33%)、肾经(433 次、15.47%)为主.结论 临床多以平肝熄风、清热及安神类矿物药治疗抑郁症,具有重镇安神、平肝潜阳、定惊明目功效的咸寒、甘寒药物较常用.

目的 探讨鸦胆子油乳对大鼠体内紫杉醇药代动力学的影响.方法 将 16 只SD大鼠随机分为紫杉醇联用鸦胆子油乳组(PTX + BJOE组)和紫杉醇组(PTX组),各 8 只.PTX + BJOE组大鼠腹腔注射鸦胆子油乳注射液 2.7 mL/kg,PTX组大鼠腹腔注射等量生理盐水,连续 5d,最后 1d给药 30 min后,两组大鼠均腹腔注射紫杉醇注射液 3.5 mL/kg;给药后 0,0.083,0.5,1,2,4,8,24,48h时经大鼠眼眶静脉采血,并分离血浆.采用超高效液相色谱-质谱法测定大鼠血浆中紫杉醇的浓度,采用GraphPad Prism 7.04软件绘制血药浓度-时间曲线,使用DAS 2.0 软件计算药代动力学参数.结果 与PTX组比较,PTX + BJOE组大鼠给药后 0.5,4,8,24h时紫杉醇的血药浓度均显著升高(P<0.05);PTX + BJOE组大鼠血浆中 0-∞时血药浓度-时间曲线下面积(AUC0-∞)显著升高(P<0.05),半衰期(t1/2)显著缩短(P<0.05);达峰浓度(Cmax)升高,表观分布容积(Vd)降低,但均无显著差异(P>0.05).结论 鸦胆子油乳联用紫杉醇可能存在相互作用,鸦胆子油乳可能会使紫杉醇的血药浓度增大、药效增强,临床联用时可能需减小紫杉醇的剂量.

目的 基于网络药理学和分子对接技术探讨万应胶囊治疗急性上呼吸道感染伴发热的作用靶点与分子机制.方法 从中药系统药理学数据库与分析平台(TCMSP)、草药成分和靶标数据库(HIT)、本草组鉴数据库(HERB)检索万应胶囊的活性成分,通过SwissTargetPrediction平台预测潜在的作用靶点.在GeneCards、OMIM、DisGeNET数据库中筛选急性上呼吸道感染伴发热的潜在作用靶点.采用STING平台构建PPI网络,通过Cytoscape软件进行网络拓扑计算并筛选潜在关键靶点,通过R软件进行GO功能及KEGG通路富集分析,构建"中药-活性成分-靶点-信号通路-疾病"网络.采用分子对接技术预测潜在活性成分和靶点结合性能.结果 共筛选万应胶囊有效活性成分51种,相应基因靶点707个,疾病的相关靶点754个.万应胶囊治疗急性上呼吸道感染伴发热的潜在靶点123个,其中关键靶点为STAT3、HRAS、SRC、PIK3R1、PTPN11.KEGG富集分析显示,关键信号通路包括HIF-1、AGE-RAGE、PI3K-Akt等.分子对接结果显示,arvenin Ⅰ和6-阿魏酰梓醇可能是核心活性化合物.结论 万应胶囊通过多组分、多靶点及多通路协同机制干预急性上呼吸道感染伴发热,其与细胞增殖和代谢、磷酸化调节、免疫系统、激酶活性及信号受体结合等机制密切相关.

BackgroundPatients with systemic lupus erythematosus (SLE) are at increased risk of cardiovascular disease (CVD) compared to the general population. However, little is known about the effects of tobacco smoking on CVD in patients with SLE.ObjectiveTo systematically review and summarize the available literature regarding the effects of tobacco smoking on developing CVD in patients with SLE.MethodsWe retrieved relevant studies from the following databases: PubMed, EMBASE, Web of Science and China National Knowledge Internet (CNKI) database. Two reviewers independently reviewed the eligible studies, assessed their validity, and extracted relevant data. Sensitivity and subgroup analyses were performed to distinguish sources of heterogeneity.ResultsA total of 10 studies, which comprised 6984 participants, were included in the analysis. The overall quality of evidence was rated as moderate to low. The smoking prevalence among CVD patients was 39.28% (271/690), which was higher than 31.36% (1974/6294) among non-CVD patients. Compared with never-smokers, the risk of developing CVD in current smokers was 1.42 (95% CI: 1.21–1.66). No significant publication bias was found in our meta-analysis.ConclusionsIn spite of the several negative results, this study found that current smokers with SLE have an increased risk of developing CVD, although most of the included studies were in low-to-moderate quality.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022338109.

中成药是我国医疗卫生体系中药品的一大特色和优势,其剂型多样,品种繁多,临床应用十分广泛.据相关统计,我国获批国产中药批文共59 474个,共涉及中成药品种9 629个,剂型42种.综合性医院中,西医所开出的中成药占医疗机构全部售出中成药的84％[1-2].随着中成药临床使用范围的扩大,安全性问题也日趋严峻,除中成药的质量状况外[3],临床合理应用方面更为明显,如用药过量,重复用药、联合用药不当,超用药禁忌、功效及毒副作用考虑不周等[4-5].近年来发生的"鱼腥草注射液事件""双黄连注射液事件""茵栀黄注射液事件"等中成药安全性事件,对中成药的临床应用产生了巨大的不良影响,其中重要的原因就是中成药临床使用缺乏科学的、符合中成药特点的、实用性强的规范性文件.国家发布了《中成药临床应用指导原则》(2010版),但从实施效果来看,中成药临床合理使用仍需进一步规范,亟需制定具有实用性、针对性、科学性的中成药临床使用规范.

中医药是我国医药卫生体系的重要组成部分，中医药有其独特的理论体系、临床实践及科学研究。中成药是在中医药理论指导下，以中药饮片为原料，按规定处方和制剂工艺加工而成的中药制剂 [1] ，具有传承与创新并重的属性。

目的:系统评价金芪降糖片与4种不同中药方剂或中成药相比治疗2型糖尿病(T2DM)患者的临床有效性.方法:计算机检索PubMed、Web of Science、Cochrane Library、Embase、CNKI、WanFang Data、SinoMed、VIP数据库,搜集关于金芪降糖片及葛根芩连汤、津力达颗粒、大柴胡汤、天芪降糖胶囊单独应用或与二甲双胍联用治疗T2DM的随机对照试验(RCT),检索时限均为建库至2021年3月1日,由两位研究者筛选文献并提取相关信息并评价纳入研究的偏倚风险后,采用WinBUGS 1.4.3软件联合Stata 16.0软件进行贝叶斯网状Meta分析,并根据曲线下面积结果进行有效性比较及排序.结果:最终纳入71个RCT,共包括6882例患者,涉及9种干预措施.网状Meta分析结果显示,在中西药联用方面,5种中药与西药联用的疗效都明显高于西药对照组,并且在降低餐后2h血糖(2hPG)和糖化血红蛋白(HbA1c)方面,金芪降糖片联用二甲双胍的疗效优于其他4种中药.降低空腹血糖(FBG)方面,中药单用及联用与二甲双胍的对比结果为:葛根芩连汤+二甲双胍＞津力达+二甲双胍＞大柴胡汤+二甲双胍＞葛根芩连汤＞金芪降糖+二甲双胍＞金芪降糖＞津力达＞大柴胡汤＞天芪降糖+二甲双胍＞二甲双胍.降低2hPG方面,对比结果为:葛根芩连汤＞金芪降糖+二甲双胍＞葛根芩连汤+二甲双胍＞津力达+二甲双胍＞天芪降糖+二甲双胍＞大柴胡汤+二甲双胍＞津力达＞金芪降糖＞二甲双胍＞大柴胡汤.降低HbA1c方面,对比结果为:金芪降糖+二甲双胍＞葛根芩连汤+二甲双胍＞大柴胡汤+二甲双胍＞葛根芩连汤＞津力达+二甲双胍＞天芪降糖+二甲双胍＞津力达＞二甲双胍＞大柴胡汤.结论:当前证据显示,与葛根芩连汤、津力达颗粒、大柴胡汤、天芪降糖胶囊比较,金芪降糖片单独或与西药联合应用于气虚内热证T2DM患者具有一定的临床有效性.

目的 了解中药临床药师培训结业学员返岗后的工作现状.方法 采用"问卷星"在线调研平台,通过微信方式向已结束中药临床药师培训的学员发放调查问卷,收集结业学员的工作地、所在医院级别、年龄、职称等基本信息,以及返岗后的工作去向、工作内容、临床认可度、培训建议等信息,分析结业学员的工作现状.结果 中药临床药师培训学员已覆盖全国30个省、自治区、直辖市,共结业878人,回收调查问卷757份.学员返岗后从事临床药学工作的占77.94％;每周参与临床工作时间占比超过1/2周的仅25.25％,主要原因是科室其他事务繁忙,学员认为能胜任自身工作或能获得临床认可的分别占97.80％和73.73％,92.71％的学员愿意继续从事临床药学工作;96.30％的学员觉得培训非常受益,对培训基地的建议主要集中在培训内容、培训方式、带教等方面.结论 绝大部分学员中药临床药师培训结业学员返岗后愿意并能从事临床药师工作,培训基地将不断优化培训模式和内容,努力为中药临床药师行业的发展贡献力量.

目的 探讨临床药师参与糖尿病足合并多种并发症的治疗及药学监护的方法和作用.方法 临床药师参与1例糖尿病足合并多种并发症患者患肢感染的治疗,为临床提供药物治疗资料,分析患者在治疗过程中的疗效并监测患者用药的安全性,根据药物治疗情况及时开展用药教育.结果 本病例糖尿病足合并多种并发症接受多药治疗.糖尿病足溃疡主要以中药汤剂治疗,辅助以溃疡面局部换药,症状得到较好控制.结论 临床开展中药学和药学监护有利于患者安全、有效用药,能提高临床治疗水平,促进临床合理用药.

Background: Multiple studies have revealed that idiopathic pulmonary fibrosis (IPF) patients are more at risk for cardiovascular diseases and that many IPF patients receive cardiovascular medications like statins, angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), and anticoagulants. Existing studies have reported divergent findings on the link between cardiovascular medications and fibrotic disease processes. The aim of this study is to synthesize the evidence on the efficacy of cardiovascular medications in IPF.Methods: We searched studies reporting the effect of cardiovascular medications on IPF in the PubMed, Embase, Web of Science, Cochrane Library, and two Chinese databases (China National Knowledge Infrastructure database and China Wanfang database). We calculated survival data, forced vital capacity (FVC) decline, and IPF-related mortality to assess the efficacy of cardiovascular medications in IPF. We also estimated statistical heterogeneity by using I2 and Cochran Q tests, and publication bias was evaluated by risk of bias tools ROBINS-I.Results: A total of 12 studies were included in the analysis. The included studies had moderate-to-serious risk of bias. Statin use was associated with a reduction in mortality (hazard ratio (HR), 0.89; 95% CI 0.83–0.97). Meta-analysis did not demonstrate any significant relationship between statin use and the FVC decline (HR, 0.86; 95% CI 0.73–1.02), ACEI/ARB use, and survival data (HR, 0.92; 95% CI 0.73–1.15) as well as anticoagulant use and survival data (HR, 1.16; 95% CI 0.62–2.19).Conclusion: Our study suggested that there is a consistent relationship between statin therapy and survival data in IPF population. However, there is currently insufficient evidence to conclude the effect of ACEI, ARB, and anticoagulant therapy on IPF population especially to the disease-related outcomes in IPF.

目的 采用网络问卷调查平台调查全国中医类医院药学人才发展的情况,分析其影响因素并探讨对策.方法 设计网络调查问卷,通过中华中医药学会医院药学分会向全国中医类医院调查药学人才发展情况,同时调查部分综合性医院及专科医院作为参考对比,要求由医院人事部门领导或药学部主任填写,同一医院只填写一份调查表.结果 本次调查收回有效问卷1 198份,调查显示我国药学人员占比偏低(6.89％),中药职称人员占比药学人员比例较低(42％),中药职称药师的职称以药师为主,基层医院中、高级职称人员严重不足,各医院的人员类型均以在编人员为主,而业务量大的医院尝试去使用劳务租赁及医药企业延伸人员.结论 中药学人员在医院的比例及职称基础薄弱,人员配置不足,有待进一步鼓励和提升中药人员的素质.